The use of dipeptidyl peptidase 4 (DPP-4) inhibitors, especially vildagliptin, in patients with diabetes continues to be associated with an increased risk of bullous pemphigoid. In the most recent evidence, a large retrospective case-control study found patients with diabetes and bullous pemphigoid were more likely to be treated with DPP-4 inhibitors (39%) than patients with ...
Bullous pemphigoid risk seen with DPP-4 inhibitors in diabetes
By Mardi Chapman
7 Feb 2019